Introduced
Underlined text would be added to current law. Struck-through text would be removed.
| 89R16149 BEE-F | ||
| By: Gervin-Hawkins | H.B. No. 3785 |
| A BILL TO BE ENTITLED | |
| AN ACT | |
| relating to labeling requirements for compounded drug products. | |
| BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | |
| SECTION 1. Subchapter D, Chapter 562, Occupations Code, is | |
| amended by adding Section 562.157 to read as follows: | |
| Sec. 562.157. LABELING OF COMPOUNDED DRUG PRODUCTS. (a) | |
| This section applies to: | |
| (1) a pharmacy that compounds a sterile or non-sterile | |
| preparation; and | |
| (2) a manufacturer or other entity that compounds a | |
| drug intended to be distributed: | |
| (A) through a telepharmacy service; | |
| (B) by over-the-counter sale; or | |
| (C) directly from a pharmacist to a patient. | |
| (b) A pharmacist may not furnish or dispense a compounded | |
| drug to a patient unless the drug is labeled with the following | |
| information: | |
| (1) the patient's name; | |
| (2) the name, address, telephone number, and license | |
| number of: | |
| (A) the pharmacy furnishing or dispensing the | |
| compounded drug; or | |
| (B) the pharmacy that prepared the compounded | |
| drug, if that is not the same pharmacy described by Paragraph (A); | |
| (3) the statement "Compounded Drug, Substitute for | |
| (insert name of drug applicable to the compound)"; | |
| (4) all active ingredients used to prepare the | |
| compounded drug; | |
| (5) the compounded drug's beyond-use date, as | |
| determined by the pharmacist using appropriate documented | |
| criteria; | |
| (6) the quantity or amount of the compounded drug in | |
| the container dispensed to the patient; | |
| (7) appropriate ancillary instructions, including: | |
| (A) storage instructions; and | |
| (B) cautionary instructions or statements, | |
| including any hazardous drug warning; | |
| (8) directions for use, including all appropriate: | |
| (A) dosage directions; and | |
| (B) other administration directions, including | |
| as applicable, the appropriate dosage level per time interval; | |
| (9) any side effects noted from trials, research, and | |
| other appropriate information sources; | |
| (10) whether the compounded drug was prepared in a | |
| sterile facility or a non-sterile facility; and | |
| (11) whether the compounded drug was prepared in a | |
| location outside of the pharmacy that furnishes the drug to the | |
| patient. | |
| (c) The board shall adopt rules regarding the labeling | |
| requirements of Subsection (b) in accordance with other existing | |
| labeling requirements. | |
| SECTION 2. Not later than December 1, 2025, the Texas State | |
| Board of Pharmacy shall adopt the rules required by Section | |
| 562.157, Occupations Code, as added by this Act. | |
| SECTION 3. This Act takes effect September 1, 2025. |
Official text from the Texas Legislature. Formatting has been adapted for reading on Ratifi.